Sweet Urine; good times never seemed so good! episode artwork

EPISODE · Dec 3, 2024 · 17 MIN

Sweet Urine; good times never seemed so good!

from For Kidneys Sake

Do you have a question? Send it now...The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS)In this episode, Jeremy Levy and Andrew Frankel discuss the game-changing role of SGLT2 inhibitors in treating chronic kidney disease (CKD). These drugs, initially developed for diabetes, have shown remarkable benefits in slowing CKD progression, reducing cardiovascular risks, and delaying dialysis. They cover the key patient groups, prescribing tips, and how to use these medications safely and effectively.Top Three Takeaways:1. Broad Benefits Beyond Diabetes: SGLT2 inhibitors significantly slow CKD progression, reduce cardiovascular risks, and delay the need for dialysis, benefiting patients with or without diabetes.2. Who Should Get Them:Heart failure patients.CKD patients with or without diabetes and/or albuminuria.Patients with GFR between 20-45, regardless of urine albumin levels.3. Safety and Usage Tips:Avoid type 1 diabetes or "type 1-like" patients.Manage minor side effects (e.g., fungal infections) and provide "Sick Day Guidance" to minimise risks like ketoacidosis.This episode provides practical insights and actionable advice for clinicians managing CKD patients.Resource Links:NICE GUIDELINES [NG203] chronic kidney disease: assessment and management Overview | Chronic kidney disease: assessment and management | Guidance | NICENorthwest London CKD guidelines for primary care: Chronic kidney disease (nwlondonicb.nhs.uk)The purpose of this podcast is to inform and educate health care professionals working in the primary care and community setting. The content is evidence based and consistent with NICE guidelines and North West Guidelines available at the time of publication.The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement.You can also join the community by signing up to our newsletter here Produced by award-winning media and marketing specialist Heather Pownall of Heather's Media Hub 

Episode metadata supplied by the publisher feed · Published Dec 3, 2024

Embed this episode

Do you have a question? Send it now... The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS) In this episode, Jeremy Levy and Andrew Frankel discuss the game-changing role of SGLT2 inhibitors in treating chronic kidney disease (CKD). These drugs, initially developed for diabetes, have shown remarkable benefits in slowing CKD progression, reducing cardiovascular risks, and delaying dialysis. They co...

Distinct summary based on available episode metadata or transcript content.

Ready to play

Sweet Urine; good times never seemed so good!

0:00 17:40

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of For Kidneys Sake?

This episode is 17 minutes long.

When was this For Kidneys Sake episode published?

This episode was published on December 3, 2024.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this For Kidneys Sake episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!